THE WOODLANDS, Texas, March 31 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it will hold its Annual R&D Day on Thursday, April 8, 2010 from 7:30 a.m. to 11:00 a.m. Eastern Time in New York, New York. Members of Lexicon's senior management team will provide in-depth reviews of the company's clinical programs, including LX4211 for diabetes, LX1031 for irritable bowel syndrome, LX1032 for carcinoid syndrome, and LX2931 for rheumatoid arthritis. In addition, the meeting will feature a presentation on diabetes by William Cefalu, M.D., including a discussion of the present unmet medical needs and where SGLT inhibitors fit in the current landscape of diabetes treatments. Dr. Cefalu is the Douglas L. Manship Sr. Professor of Diabetes, and Chief of the Joint Program on Diabetes, Endocrinology and Metabolism at Pennington Biomedical Research Center and the Louisiana State University Health Science Center School of Medicine.
Advertisement
A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com. An archived version of the webcast will be available after the event on the company's website.
Advertisement
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by the company's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.
